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The applications of pharmaceutical andmedical nanosystems are among themost intensively investigated fields in nanotechnology.
A relevant point to be considered in the design and development of nanovehicles intended for medical use is the formation of
the “protein corona” around the nanoparticle, that is, a complex biomolecular layer formed when the nanovehicle is exposed to
biological fluids. The chemical nature of the protein corona determines the biological identity of the nanoparticle and influences,
among others, the recognition of the nanocarrier by the mononuclear phagocytic system and, thus, its clearance from the blood.
Recent works suggest that Surface Plasmon Resonance (SPR), extensively employed for the analysis of biomolecular interactions,
can shed light on the formation of the protein corona and its interaction with the surroundings.The synthesis and characterization
of solid lipid nanoparticles (SLN) coated with polymers of different chemical nature (e.g., polyvinyl alcohol, chitosans) are reported.
The proof-of-concept for the use of SPR technique in characterizing protein-nanoparticle interactions of surface-immobilized
proteins (immunoglobulin G and bovine serum albumin, both involved in the formation of the corona) subjected to flowing SLN
is demonstrated for non-chitosan-coated nanoparticles. All assayed nanosystems showmore preference for IgG than for BSA, such
preference being more pronounced in the case of polyvinyl-alcohol-coated SLN.
1. Introduction
Pharmaceutical and medical applications of nanosystems
represent a growing area in the flourishing field of nanotech-
nology, including developments in advanced pharmaceutical
nanocarriers and nanodiagnostics [1–3]. Nanosized carriers
of very diverse composition are being actively investigated,
including metallic, polymeric, ceramic, and lipidic nanopar-
ticles and also hybrid systems by combining such materials
[4, 5].
One of the main limitations of these kinds of delivery
systems is their short circulation time due to the opsonization
phenomenon and subsequent uptake by the mononuclear
phagocytic system (MPS). After exposure of nanocarriers
to biological fluids, biomolecules are rapidly adsorbed onto
their surface forming the protein corona.The corona compo-
sition determines the biological identity of the nanoparticle
and influences its toxicity, biological fate, circulation time,
cell uptake, and drug release kinetics [6, 7]. At first, the
protein corona includes considerable amounts of low-affinity
proteins which abound in the biological medium. Over time,
the composition of the corona is enriched with high affinity
proteins [7]. Interestingly, some of the adsorbed proteins are
opsonins which promote the uptake and degradation of the
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nanoparticles by the cells of the mononuclear phagocytic
system (MPS) (mainly located in the liver, spleen, and
lymph nodes). Among the proteins commonly found in
the corona, IgG and proteins involved in the complement
pathway typically act as opsonins (promoting uptake by
MPS) whereas serum albumin and apolipoproteins enhance
circulation time [8]. The clearance of the nanoparticles by
the MPS reduces the bioavailability of the encapsulated
drug [9, 10]. A considerable amount of evidence, however,
indicates that this phenomenon can be reduced by coating the
nanoparticles with different polymeric substances [11–13].
Lipid-based nanosystems stand out because of their
nontoxic, biocompatible and environmentally friendly com-
position. In fact, most of the pharmaceutical nanosystems
that have received approval from national health authorities
and are already in use in the clinics are of lipidic nature
(liposomes) [14]. Solid lipid nanoparticles (SLN), consisting
in a solid lipid core matrix stabilized by surfactants, are of
particular interest to encapsulate lipophilic drugs [15]. SLN
are not only versatile with respect to their composition, but it
is also possible to regulate both their particle size and surface
characteristics [15]. They are relatively easy to prepare with
“green” procedures, resulting in a final product that displays
good physicochemical stability compatible with long-term
storage, lyophilization, and sterilization processes [16, 17].
Surface Plasmon Resonance (SPR) is a label-free detec-
tion method which is particularly suitable for biomolecular
interactions studies, allowing high sensitivity measurements
in real time. This optical technique is based on the changes
that occur in the refractive index due to modifications in
the chemical composition in the proximity of thin metal
layers (typically gold and silver) that constitute the sensor
chips of the SPR equipment [18–21]. The study of protein-
nanoparticles interactions by SPR can be performed in two
ways; one entails the flow of proteins onto NP immobilized
on the SPR sensor surface and the other involves the immo-
bilization of the protein and the injection of nanoparticles
throughout the fluidic system.Ahigher sensitivity is expected
for the latter option due to the higher mass of the NP provid-
ing that the binding of the proteins to the sensor surface does
not alter their typical configuration regarding protein/NP
interactions. Previous SPR studies on the interactions of
nanovehicles with proteins of the bloodstream include the
investigation of the corona formation by employing serum
or plasma [22, 23] and the interaction of nanoparticles with
individual proteins known to adsorb onto the surface of
nanocarriers [24], an approach that has been considered for
the present experimental design.
In this work the synthesis of SLN by ultrasonication
of cetyl esters mixture in a dispersant agent (Poloxamer
188) and, in some cases, polyvinyl alcohol or chitosan as
chemical coatings is reported.The particle size, zeta potential,
and polydispersity index of the obtained SLN solutions are
characterized by Dynamic Light Scattering- (DLS-) based
measurements. Morphology and size distribution are cor-
roborated by Transmission Electron Microcopy (TEM). The
nanoparticle size in the presence of serum is also char-
acterized by DLS. SPR is then used to monitor protein-
nanoparticle interactions involved in the formation of the
corona, by immobilizing selected proteins of the corona in the
sensor surface that is subjected to the flow of SLN solutions.
As a proof-of-principle, two proteins of the corona with
opposite effects on the circulation time in the bloodstream
are chosen for the SPR experiments: IgG (that promotes the
clearance of the nanovehicle by the MPS) and BSA (that
enhances circulation time).
2. Experimental
2.1. Reagents and Materials. The cetyl esters mixture Cro-
damol SS (melting point ∼ 44∘C) was kindly donated by
Croda (Argentina). Pluronic F68, polyvinyl alcohol (PVA,
mol wt = 13–23 kDa, 98.0 hydrolyzed), low and medium
molecular weights chitosans (50–190 kDa and 190–310 kDa,
resp., 75–85% deacetylated), Bovine Serum Albumin (BSA,
MW = 66.5 kDa.), 11-mercaptoundecanoic acid (MUA),
N-hydroxysuccinimide (NHS), ethanolamine hydrochlo-
ride, andN-(3-dimethylaminopropyl)-N󸀠-ethylcarbodiimide
hydrochloride (EDC) were purchased from Sigma-Aldrich
(St. Louis, Mo, USA). Potassium chloride, sodium chlo-
ride, sodium dihydrogen phosphate, and disodium hydro-
gen phosphate were obtained from J. T. Baker (Pasadena,
Ca, USA). Sodium carbonate was purchased from Biopack
(Buenos Aires, Argentina). Commercial gold substrates
(SPR102-AU) were obtained from BioNavis (Tampere, Fin-
land). The IgG antibody used in the experiments is mono-
clonal IgG1 anti-DNP 112D5 [25] and it was kindly provided
by Drs. Guillermo Docena and Martin Rumbo from IIFP
(CONICET-UNLP), La Plata (Argentina).
2.2. Synthesis of Solid LipidNanoparticles. SLNwere prepared
by the ultrasonication method [26]. Briefly, 400mg of lipid
(2.0%w/v) was melted in a water bath at 70∘C. Later, hot
aqueous solution (70∘C, 20ml) containing 3% (w/v) of
Pluronic F68 was added to the lipid phase. Immediately,
the mixture was ultrasonicated for 30min (50% amplitude)
using an ultrasonic processor (130W, Cole-Parmer, USA)
equipped with a 3mm titanium tip. Then, the dispersion
was cooled down at room temperature and stored at 5∘C
[27, 28].The obtained SLN formulation is denoted, fromhere,
P188. The same synthesis, but using 4.5% (w/v) of Pluronic
F68, yielded a SLN formulation called P188+. Three SLN
formulations including coating polymers were prepared, by
adding polyvinyl alcohol, lowmolecular weight chitosan, and
medium molecular weight chitosan to the aqueous phase
(called PVA, CL, and CM, resp.). In the case of SLN formu-
lations CL and CM, the procedure involved the dissolution
of 2.0% (w/v) chitosan in 0.1% acetic acid at pH 4.0 and
the preheating to 70∘C before the addition of the polymer to
the aqueous phase. The compositions of all formulations are
shown in Table 1.
2.3. Particle Size, Zeta Potential (𝜁), and Polydispersity Index
(PDI). The mean diameter and size distribution were mea-
sured by photon correlation spectroscopy (PCS) (Nano
ZS Zetasizer, Malvern Instruments Corp, UK) at 25∘C in
polystyrene cuvettes with a path length of 10mm. The zeta
potential was determined by laser Doppler anemometry also
Journal of Nanomaterials 3
Table 1: Composition of the aqueous phase of SLN formulations∗. In all cases, the lipid used was Crodamol SS.
Formulation∗ Aqueous phase components Composition (%)
SLN P188 Pluronic F68 3
SLN PVA Pluronic F68 : PVA 2.5 : 0.5
SLN CM Pluronic F68 :MMWC 2.5 : 0.5
SLN CL Pluronic F68 : LMWC 2.5 : 0.5
SLN P188+ Pluronic F68 4.5
using the Nano ZS Zetasizer. Measurements were performed
in capillary cells with path lengths of 10mm, using deionized
water obtained fromaMilli-Q system andphosphate buffered
saline (PBS) as diluting media. Additional measurements
were accomplished in SLN formulations preincubated in
Fetal Bovine Serum (FBS) during one hour [29]. In all cases
the measurements were performed in triplicate.
2.4. Transmission Electron Microscopy (TEM). The nanopar-
ticle dispersion was ten times diluted with ultrapure water
and a drop of the dispersion was spread onto a collodion-
coated Cu grid (400 mesh). Liquid excess was drained
with filter paper. One drop of phosphotungstic acid was
added to the dispersion, for contrast enhancement. Finally,
TEM analysis was performed using Jeol-1200 EX II-TEM
microscope (Jeol, MA, USA.).
2.5. Preparation of the Sensor Surfaces. Single thiol SAMs
were obtained by overnight incubation of the gold substrates
in 50 𝜇MMUA ethanolic solution at room temperature. The
obtained surfaces were washedwithMilli-Qwater and dried
in a stream of nitrogen before SPR measurements.
2.6. SPRMeasurements. Measurements were performedwith
a SPR Navi 210A (BioNavis) instrument. The setup is
equipped with two incident laser wavelengths, 670 nm and
785 nm, two independent flow channels, and inlet tubing
and outlet (waste) tubing. In this work, both of the flow
channels were measured in parallel with 670 nm incident
light. The measurement temperature was kept constant at
22∘C, and the flow rate used for protein immobilization and
for monitoring the SLN interactions with the immobilized
proteins was 10𝜇L/min.
Theworkingmodewas “in parallel,” by immobilizing IgG
in one flow cell and BSA in the other. The immobilization of
the proteins to the single SAMs was performed by the well-
known carbodiimide coupling reaction [30]. The first step is
the activation of the MUA-carboxyl groups on the surface
with a mixture of 0.1M EDC and 0.1M NHS to give reactive
succinimide esters. IgG 50 𝜇g/mL in 10mM sodium acetate
pH 4.6 and BSA 100 𝜇g/mL in 10mM sodium acetate pH
4 are then passed through flow cells 1 and 2, respectively,
over the surface, and the esters react spontaneously with
primary amine groups of the proteins. The immobilization
process concludes by blocking remaining succinimide esters
using 1M ethanolamine, pH 8.5. A simplified scheme of the
sensor surface is shown in Figure 1. The same schedule of
carbodiimide coupling reaction, but flowing buffer solution
instead of protein solution, was performed to obtain control
surfaces.
SLN solutions (2mg/ml in PBS pH 7.4) were passed
during 10 minutes followed by an injection of PBS pH 7.4
as running buffer and, to remove the bound SLN from
the sensor surfaces, 1-minute regeneration steps with Triton
X-100 1%. The SPR signal assigned to each SLN solution
corresponded to the plateau of the SPR response in the time
in between the end of the SLN injection and the start of the
regeneration step. Experiments were performed in triplicate.
3. Results and Discussion
3.1. Synthesis and Characterization of the SLN. SLN of dif-
ferent chemical composition with a common lipidic core
composed of cetyl esters mixture and dispersed in poloxamer
188 as emulsifying agent were prepared by sonicationmethod
and, in some cases, modified by polymer coatings with
PVA or chitosans. The mean diameter, zeta potential, and
polydispersity index of the prepared SLN formulations were
measured in aqueous solution and in PBS 1x as diluting
medium (Tables 2(a) and 2(b), resp.). The particle size of the
SLN ranges between 140 and 200 nm, being comparable to the
mean diametermeasured inwater or PBS in the case of P188+,
CL, and CM. An increase in the particle size when the SLN
is measured in PBS is observed in P188 and PVA, probably
due to the change in the hydrodynamic diameter of these
nanovehicles in the high ionic strengthmedium.The polydis-
persity index of the obtained nanoparticles ranged between
0.14 and 0.23, verifying in all cases the small polydispersity of
the SLN solutions. It is well known that size influences both
cell uptake and drug release kinetics in nanoparticles and
other particulate systems [31–33]. Accordingly, it is desirable
to attain low polydispersity since this is expected to result
in a more predictable and homogeneous behavior within the
targeted biological system.
In relation to the surface charge of the formulations,
P188, P188+, and PVA appear to be negatively charged in
both media, which is an interesting feature to maintain their
stability and avoid possible aggregations. On the other side,
significant changes in zeta potential values for chitosan-
coated nanoparticles are observed by changing deionized
water for PBS in PCS measurement. Both CL and CM are
characterized by positive zeta potentials in deionized water,
in accordance with the positive surface charge expected from
the chemical polymer structure of the coating. However,
determination of zeta potential in PBS reflects a shift to
more neutral values, which can be explained considering the
4 Journal of Nanomaterials
Table 2
(a) Mean diameter (𝑍-average), polydispersity index (PI), and zeta potential (𝜁) of different formulations of solid lipid nanoparticles measured in deionized
water. Data shown as mean ± standard deviation, 𝑛 = 3.
Sample Mean diameter (nm) PDI 𝜁 (mV)
SLN P188 199 ± 3 0.10 ± 0.03 −6.4 ± 0.9
SLN PVA 161 ± 1 0.213 ± 0.006 −1.5 ± 0.1
SLN CM 154 ± 3 0.183 ± 0.002 22 ± 1
SLN CL 151 ± 3 0.18 ± 0.02 13 ± 2
SLN P188+ 142 ± 1 0.154 ± 0.008 −1.1 ± 0.1
(b) Mean diameter (𝑍-average), polydispersity index (PI), and zeta potential (𝜁) of different formulations of solid lipid nanoparticles measured in PBS as
diluting medium. Data shown as mean ± standard deviation, 𝑛 = 3.
Sample Mean diameter (nm) PDI 𝜁 (mV)
SLN P188 207 ± 2 0.16 ± 0.02 −2.8 ± 0.5
SLN PVA 174 ± 1 0.237 ± 0.009 −6.1 ± 0.1
SLN CM 152.3 ± 0.3 0.175 ± 0.007 0.7 ± 0.5
SLN CL 146.5 ± 0.8 0.16 ± 0.01 2.2 ± 0.2
SLN P188+ 142 ± 1 0.16 ± 0.01 −5.2 ± 0.4
IgG (or BSA)
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Figure 1: Simplified representation of the sensor surface to demonstrate the distinct layers of interest in the sensor surface and the correlation
of the interactions that occurs in the sensor surface and the observed sensorgram. Roman numerals indicate (I) the protein layer after
immobilization onto the thiol self-assembled monolayer, (II and III) SLN interaction with immobilized proteins at different times of the
flow of SLN solutions, and (IV) the interaction of SLN-protein after restoration of buffer flow.
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Figure 2: TEM images (60,000x) showing the effect of increasing surfactant concentration on SLN preparation: (a) SLN P188 and (b) SLN
P188+ (b).
interaction between the positive surface charges of chitosan
with negatively charged phosphate ions [34].This interaction
masks the positive charge of chitosan-coated SLN and pro-
duces particles with zeta potential values close to neutrality.
More information about the size, distribution, and mor-
phology of SLNwas obtained by TEMobservations. An effect
of increasing 50% of the surfactant concentration during
SLN preparation was observed (Figure 2). While SLN P188
formulation exhibited nanoparticles around 200 nm in a
relative narrow size distribution, the SLN P188+ preparation
produced a bimodal mixture with similar nanoparticles of
200 nm in diameter but with the additional presence of
small micelles (mean diameter ≤ 50 nm), possibly due to
the surfactant excess. This result is consistent with PCS
measure, which indicated that the increase in surfactant
concentration produces a lower mean diameter and higher
PDI of nanoparticles.
On the other side, the effect of biopolymers addition
during SLN preparation was also studied by TEM (Fig-
ure 3). The SLN PVA were characterized by nanoparticles
in the range of 100–200 nm and covered by PVA layers.
Interconnected nanoparticles maybe by PVA bridges are
observed (Figures 3(a) and 3(b)). PCS experiments showed
that PVA formulation exhibits mean diameters of 161 ±
1 nm in water and 174 ± 1 nm in PBS indicating that these
bridges are consequence of the dryness process in the TEM
chamber. The morphology, size, and distribution of chitosan
nanoparticles seem not to bemodified by changes in theMW
of the biopolymer. In this sense, spherical SLN with a mean
diameter around 200 nm were observed (Figures 3(c)–3(f)).
3.2. DLS Measurements of SLN-Protein Corona Complexes.
In order to investigate the change in the nanoparticle size
due to the adsorption of serum proteins, DLS measurements
of SLN formulations incubated with Fetal Bovine Serum
(FBS), as a model system of biological fluid, were performed
(see Figure S1 in Supplementary Material available online at
https://doi.org/10.1155/2017/6509184). In all cases, the same
increment of the particle size is observed (around 100 nm)
when the formulations are in contact with FBS, a finding
that can be ascribed to the adsorption of serum proteins over
the SLN independently of the differences in surface charge,
chemical composition, and molecular weight of the coating
in all tested SLN formulations.
The identity of the protein corona is known to play a
fundamental role in biological adhesion [35], but due to
the complexity of its composition, we propose to study the
interaction of the nanovehicles with specific corona proteins
like BSA and IgG. Due to the well-known ability of SPR
technique to study biomolecular interactions, next we will
discuss experimental results involving the immobilization of
the proteins on the sensor surface and flowing SLN through
the microfluidic system.
3.3. SPR Study of SLN Interaction with Immobilized IgG and
BSA. Typical SPR sensorgrams resulting from the passage of
SLN solutions over immobilized IgG and BSA are shown in
Figures 4 and 5, respectively. In the figures, the SPR signal
corresponding to each formulation is indicated in red. The
SPR signal corresponding to the interaction of positively
charged chitosan-coated nanoparticles with IgG or BSA,
showed in (d) and (e) of Figures 4 and 5, is more intense in
comparisonwith the SPR signal resulting from the other SLN.
Even more, the binding of the positively charged chitosan-
coated formulations to the immobilized proteins cannot be
regenerated with Triton X-100. However, chemical treatment
with the nonionic surfactant allows recovering the sensor
surface in the case of the other SLN. It is interesting to notice
that this finding is independent of the chemical nature of the
protein immobilized on the sensor surface, suggesting that
the interaction of the SLN with proteins depends strongly
on the physicochemical surface properties of the polymer
coating. Considering that both immobilized proteins, BSA
(isoelectric point ≃ 4.7) and IgG (isoelectric point ≃ 7.0),
are negatively charged at the working pH of 7.4 and taking
into account the fact that non-chitosan-coated SLN are also
negatively charged, it could be inferred that electrostatic
forces would not play an important role in the SLN-protein
interactions.
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Figure 3: TEM images showing the effect on SLN preparation by addition of polymers observed by TEM: SLN PVA (a-b), SLNQL (c-d), and
SLN QM (e-f) at 40,000 (a, c, and e) and 60,000 (b, d, f) magnifications.
Control experiments, flowing SLNover reference surfaces
without immobilized proteins, showed negligible interaction
in the case of P188, P188+, and PVA formulations (Figure 6).
However, the chitosan-coated SLN showed roughly the same
SPR signal change in the control experiments and in the
measurements involving immobilized proteins. It is well
known that due to its chemical nature, chitosan exhibits
interactions with several surfaces and strong mucoadhesivity
[36–39]. Thus, the interaction of chitosan-coated SLN with
the surface in control experiments can be related to the
interaction between the hydrophilic surface of the ester
formed when MUA was subjected to carbodiimide coupling
and the positively charged hydrophilic CL and CM. Another
possibility is that in case that some carboxyl activated MUA
terminal groups were not blocked by ethanolamine they can
react with the nonprotonated amine groups of chitosan. It
is well known that amines and hydroxyl groups situated on
chitosan chains are responsible for chemical cross-linking.
Hydrogen bonding can also contribute to the affinity of CL
and CM with the MUA blocked surface.
In order to investigate if P188, P188+, and PVA formu-
lations show preference to interact with IgG or with BSA,
it is necessary to make a correction of the SPR signal that
gives account of the amount of immobilized protein in each
Journal of Nanomaterials 7
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Figure 4: Sensorgrams showing the SPR signal resulting from the injection of the solid lipid nanoparticles (a) P188, (b) P188+, (c) PVA, (d) CL,
and (e) CM over immobilized IgG (sensor surface: Au-MUA-IgG). Each cycle included a ten-minute injection of the SLN solution followed
by a washing step with running buffer (PBS pH 7.4). In order to remove the bound SLN from the sensor surfaces, 1-minute regeneration steps
with Triton X-100 were performed. SPR signal corresponding to each SLN was measured in a time in between the end of the SLN injection
and the start of the regeneration step (around ∼ 1250 s of each cycle, except CL nanoparticles that the SPR signal was measured at around
750 s).
experiment (Figure S2 in Supplementary Information). The
corrected SPR signals corresponding to the interactions of
the SLN and IgG or BSA are shown in Table 3. As it can
be observed, all assayed nanosystems show preference to
interact with IgG rather than BSA. Due to the fact that at pH
7.4 the surface charge of IgG is close to neutrality, another type
of interactions excluding electrostatics should be explored to
account for the experimental results.
Further studies are being carried out to validate the use
of SLN formulations composed of P188, P188+, and PVA for
their use in animal models in a next experimental step.
4. Conclusions
Solid lipid nanoparticles ranging 140–200 nm were obtained
by the ultrasonication method. Distinct surface charges
characterized the formulations, according to the chemical
coating. In all cases a small polydispersity of the SLN solu-
tions could be verified by photon correlation spectroscopy
measurements. An increment of around 100 nm in the par-
ticle diameter was observed when the SLN formulations are
incubated in FBS, finding that it can be ascribed to protein
adsorption around the nanoparticles.
8 Journal of Nanomaterials
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Figure 5: Sensorgrams showing the SPR signal resulting from the injection of the solid lipid nanoparticles (a) P188, (b) P188+, (c) PVA, (d) CL,
and (e) CM over immobilized BSA (sensor surface: Au-MUA-BSA). Each cycle included a ten-minute injection of the SLN solution followed
by a washing step with running buffer (PBS pH 7.4). In order to remove the bound SLN from the sensor surfaces, 1 min regeneration steps
with Triton X-100 were performed. SPR signal corresponding to each SLN was measured in a time in between the end of the SLN injection
and the start of the regeneration step (around ∼ 1250 s of each cycle, except CL nanoparticles that the SPR signal was measured at around
750 s).
The SPR experiments performed in this work verified dif-
ferent proclivity of non-chitosan-coated SLN to interact with
IgG with respect to BSA, a fact that can be related to different
circulations times in the bloodstream. Due to the complexity
and the relative abundance of proteins of the plasma, this
hypothesis should be confirmed in future in vivo studies. In
the case of chitosan-coated SLN, the proposed strategy did
not yield results that could gain information about the affinity
of the nanoparticles and the studied proteins. However, the
finding that these nanoparticles strongly interact with the
sensor surface is in accordance with the fact that chitosan
shows affinity with a variety of surfaces.
We demonstrate that SPR is a suitable technique to
evaluate the interactions between blood proteins and non-
chitosan-coated SLN. In these cases it is possible to obtain
information about the different relative affinities of the
formulations and the studied proteins, by correcting the
SPR signal change for the amount of immobilized protein
in the sensor surface. The approach discussed in this paper
can be extended to study the interactions of non-chitosan-
coated SLN with other components of the protein corona
like proteins of the complement pathway and fibrinogen.
Therefore, the application of SPR can be considered as a
promising tool for the evaluation of SLN-protein interactions
Journal of Nanomaterials 9
Table 3: Normalized SPR signal for each SLN formulation (for more detail concerning the calculation see Figure S2 in Supplementary
Information). ∗Ratio between the normalized SPR signal for immobilized IgG and the normalized SPR signal for immobilized BSA.
Normalized SPR signal
Sample Sensor surface
Au-MUA-IgG Au-MUA-BSA IgG/BSA∗
P188 0.78 0.13 6.00
P188+ 1.71 0.17 10.05
PVA 1.44 0.20 7.20
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Figure 6: Sensorgrams showing the SPR signal resulting from the injection of the solid lipid nanoparticles (a) P188, (b) P188+, (c) PVA, (d)
CL, and (e) CM over control surface without immobilized protein (sensor surface: Au-MUA). Each cycle included a ten-minute injection of
the SLN solution followed by a washing step with running buffer (PBS pH 7.4). SPR response arising from the interaction of chitosan-coated
SLN and the control surface corresponds to the stabilization of the signal after the end of the SLN injection (at around 1000 s).
10 Journal of Nanomaterials
in vitro, as well as for predicting the blood clearance of
liposomes and likely other nanocarriers in vivo.
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